Salta al contenuto principale
Passa alla visualizzazione normale.


Update on capecitabine alone and in combination regimens in colorectal cancer patients

  • Autori: Silvestris, N.; Maiello, E.; De Vita, F.; Cinieri, S.; Santini, D.; Russo, A.; Tommasi, S.; Azzariti, A.; Numico, G.; Pisconti, S.; Petriella, D.; Lorusso, V.; Millaku, A.; Colucci, G.
  • Anno di pubblicazione: 2010
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link:


Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.